First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Autor: Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)

Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern

Externí odkaz: https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b

Figure S3 from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Autor: Brian I. Rini, M. Brent McHenry, Shruti Shally Saggi, Yuko Ishii, Andre M. Murad, Sumanta K. Pal, Jeronimo R. Rodriguez-Cid, Alain Ravaud, Judit Kocsis, Scott S. Tykodi, Philippe Barthélémy, Michael R. Harrison, Frede Donskov, Thomas Powles, Saby George, Osvaldo Arén Frontera, Miriam Ficial, Jean-Christophe Pignon, Abdallah Flaifel, Robert J. Motzer, David F. McDermott, Toni K. Choueiri, Sabina Signoretti, Nizar M. Tannir

Overall survival (A) and progression-free survival (B) by baseline tumor PD-L1 expression (PD-L1 {greater than or equal to}1% and PD-L1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c09dfe5864496ac52cd3c2ee8877a762
https://doi.org/10.1158/1078-0432.22478165.v1

Table S1 from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Autor: Brian I. Rini, M. Brent McHenry, Shruti Shally Saggi, Yuko Ishii, Andre M. Murad, Sumanta K. Pal, Jeronimo R. Rodriguez-Cid, Alain Ravaud, Judit Kocsis, Scott S. Tykodi, Philippe Barthélémy, Michael R. Harrison, Frede Donskov, Thomas Powles, Saby George, Osvaldo Arén Frontera, Miriam Ficial, Jean-Christophe Pignon, Abdallah Flaifel, Robert J. Motzer, David F. McDermott, Toni K. Choueiri, Sabina Signoretti, Nizar M. Tannir

ORR in patients with sRCC and I/P-risk disease, per IRRC, by central or local pathology review.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a243ef260fae24a858d55ab8b0f496
https://doi.org/10.1158/1078-0432.22478162.v1

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Autor: Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid

Publikováno v: Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063

Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ef4fae16505a538074156c51ab25a
https://doi.org/10.1158/1078-0432.ccr-20-2063

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Autor: M. Brent McHenry, Thomas Powles, Pamela Salman, David F. McDermott, Christian Kollmannsberger, Asim Amin, Saby George, Osvaldo Arén Frontera, Shruti Shally Saggi, Scott S. Tykodi, Robert J. Motzer, Marc-Oliver Grimm, Bernard Escudier, V. Neiman, Viktor Grünwald, Brian I. Rini, Howard Gurney, Toni K. Choueiri, Raya Leibowitz-Amit, Alain Ravaud, Poul F. Geertsen, Philippe Barthélémy, Hans J. Hammers, Frede Donskov, Camillo Porta, Bohuslav Melichar, Elizabeth R. Plimack, Yoshihiko Tomita, Nizar M. Tannir

Publikováno v: Journal for Immunotherapy of Cancer
Motzer, R J, Escudier, B, McDermott, D F, Arén Frontera, O, Melichar, B, Powles, T, Donskov, F, Plimack, E R, Barthélémy, P, Hammers, H J, George, S, Grünwald, V, Porta, C, Neiman, V, Ravaud, A, Choueiri, T K, Rini, B I, Salman, P, Kollmannsberger, C K, Tykodi, S S, Grimm, M O, Gurney, H, Leibowitz-Amit, R, Geertsen, P F, Amin, A, Tomita, Y, McHenry, M B, Saggi, S S & Tannir, N M 2020, ' Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma : 42-month follow-up of a randomized phase 3 clinical trial ', Journal for immunotherapy of cancer, vol. 8, no. 2, e000891 . https://doi.org/10.1136/jitc-2020-000891
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

BackgroundThe extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26584c2f63d2463080128044f95edfb4
https://pubmed.ncbi.nlm.nih.gov/33941652